Conquering homocystinuria with engineered probiotics.

Area of Science:

• Biotechnology
• Microbiology
• Genetics

Background:

• Pyridoxine-unresponsive homocystinuria presents lifelong health challenges.
• Elevated homocysteine levels are a key concern in this condition.

Purpose of the Study:

• To evaluate the efficacy of an engineered probiotic Escherichia coli Nissle strain (SYNB1353) for reducing homocysteine.
• To assess the potential of oral probiotic delivery as a therapeutic strategy.

Main Methods:

• Development of an engineered probiotic Escherichia coli Nissle strain (SYNB1353).
• Administration of the engineered probiotic via oral delivery.
• Successful trials conducted in preclinical models (mice, monkeys) and human subjects.

Main Results:

• The engineered probiotic SYNB1353 demonstrated a significant reduction in homocysteine levels.
• Successful trials across multiple species indicate broad applicability.
• The oral delivery method proved effective.

Conclusions:

• Engineered probiotic Escherichia coli Nissle SYNB1353 is a promising candidate for managing homocysteine levels in pyridoxine-unresponsive homocystinuria.
• Further optimization and comprehensive safety assessments are necessary before clinical widespread adoption.